Erste Group Bank Has Pessimistic View of BSX FY2027 Earnings

Boston Scientific Corporation (NYSE:BSX) – Research analysts at Erste Group Bank dropped their FY2027 EPS estimates for Boston Scientific in a report issued on Wednesday, February 18th. Erste Group Bank analyst H. Engel now forecasts that the medical equipment provider will post earnings of $3.92 per share for the year, down from their previous estimate of $3.94. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share.

Several other research analysts also recently commented on the stock. Wells Fargo & Company decreased their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Weiss Ratings cut shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 price target on shares of Boston Scientific in a research note on Friday, February 6th. Needham & Company LLC decreased their price objective on Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. Finally, National Bank Financial set a $115.00 target price on Boston Scientific in a report on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $108.36.

Boston Scientific Stock Performance

NYSE:BSX opened at $74.37 on Monday. The company has a market capitalization of $110.36 billion, a price-to-earnings ratio of 38.33, a PEG ratio of 1.03 and a beta of 0.67. The business has a 50 day moving average of $88.87 and a 200 day moving average of $96.32. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific has a 1-year low of $72.69 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the business posted $0.70 earnings per share. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BSX. Steph & Co. purchased a new stake in Boston Scientific in the third quarter worth $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific in the 3rd quarter worth about $25,000. Murphy & Mullick Capital Management Corp increased its stake in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the 2nd quarter worth about $26,000. Finally, Swiss RE Ltd. purchased a new position in Boston Scientific during the 4th quarter valued at about $26,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.